| Document |
Document Title |
|
WO/2023/105411A1 |
Processes for producing a N,N-dialkyl perfluoroalkyl-sulfonamide product of the formula Rf—S(O)2—NRaRb (I) in which Rf represents fully or partially fluorinated alkyl groups with carbon 1 to 12 and Ra and Rb represents linear or bran...
|
|
WO/2023/106565A1 |
The present invention relates to a production method for a solution of bis(fluorosulfonyl)imide metal salts and, more specifically, to a production method for powder of bis(fluorosulfonyl)imide metal salts represented by Formula 2 by per...
|
|
WO/2023/101379A1 |
The present invention relates to an isocyanate composition with excellent storage stability and an optical lens manufactured from the isocyanate composition.
|
|
WO/2023/101404A1 |
The present invention relates to an isocyanate composition capable of improving transparency when applied to a product, through the suppression of discoloration and whitening, and to a preparation method therefor. The isocyanate composit...
|
|
WO/2023/023594A9 |
2‑diarylmethyl‑4‑aminotetrahydropyran derivatives are disclosed. The compounds include the following genus: or a pharmaceutically acceptable salt thereof. The compounds activate cellular PP2A, suppress oncogenic kinase signaling an...
|
|
WO/2023/087632A1 |
The present invention belongs to the field of medicinal chemistry, and specifically disclosed are an anti-inflammatory analgesic compound and the use thereof. The compound of the present invention is a compound having a structure shown i...
|
|
WO/2023/091900A1 |
The present disclosure provides compositions that provide positive allosteric modulator compounds of the beta-adrenergic receptor in combination with a beta-arrestin-biased beta-blocker, such as carvedilol, for the treatment of cardiovas...
|
|
WO/2023/076626A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
|
|
WO/2023/074936A1 |
The present disclosure relates to a bifunctional compound using a UBR box domain-binding ligand. The UBR box domain is a domain commonly present in the UBR (Ubiquitin protein ligase E3 component n-recognin) protein of the N-end rule path...
|
|
WO/2023/077057A1 |
The present disclosure provides inhibitors of the beta-catenin/B-cell lymphoma 9 interaction as well as their use in the treatment of oncological disorders. Further provided herein are methods of treating or preventing cancer in a subjec...
|
|
WO/2023/077040A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
|
|
WO/2023/064493A1 |
This invention provides compounds for the inhibition of papain-like proteases (PLpros) for the inhibition of viruses, including compounds of formula (I"), and pharmaceutically acceptable salts thereof.
|
|
WO/2023/062922A1 |
The present invention is a polyurethane, the polyurethane being characterized by containing a phenolic hydroxyl group represented by general formula (1A). Provided thereby are an electroconductive paste composition for forming a stretcha...
|
|
WO/2023/063317A1 |
The present disclosure provides a non-aqueous electrolytic solution including at least one of compounds selected from the group consisting of (I) a compound represented by general formula (1) described in the description, a compound repr...
|
|
WO/2023/053977A1 |
The present invention provides a method for producing a salt (P) of an organic cation and an organic anion, the method comprising: (1) a step for obtaining a product which contains the salt (P) by subjecting a salt (I) of the organic cat...
|
|
WO/2023/049934A1 |
Sulfonylamide and sulfonyl urea compounds, pharmaceutical compositions comprising same, and methods of treating diseases or disorders associated to amyloidogenesis activity with such compounds are disclosed.
|
|
WO/2023/048237A1 |
The present invention is a compound represented by general formula (A) [in the formula, G is -SO2R1, -CO-G1, or -C(CH3)-Ph; R1 is a C1-30 alkyl group which may have a halogen atom or a phenyl group which may have a substituent; G1 is a h...
|
|
WO/2023/046882A1 |
There is provided herein compounds of formula I and pharmaceutically acceptable salts thereof, wherein X1, X2, Z, the ring containing Q1 to Q5, m and r have meanings as provided in the description. There is also provided medical uses of ...
|
|
WO/2023/043197A1 |
The present invention provides a cannabidiol derivative, a method for preparing same, and a composition for cognitive function improvement comprising same. The novel cannabidiol derivative of the present invention has been confirmed to e...
|
|
WO/2023/043803A1 |
Disclosed herein are FABP4 and FABP5 inhibitor compounds and their use in pharmaceutical compositions for treating diseases relating to fatty acid metabolism, including cancer. Also disclosed herein are methods for preparing the disclose...
|
|
WO/2023/040106A1 |
Disclosed in the present invention is a preparation method for an acetamide compound by means of green visible-light catalysis. In the method, LED lamps are used as light sources to provide energy, and economically available aromatic ami...
|
|
WO/2023/029928A1 |
An amino lipid and an application thereof: using ethenesulfonyl fluoride (ESF), a dual-function electrophile, to build an amine head group and a hydrophobic chain into an amino lipid, fully utilizing the click chemical reaction propertie...
|
|
WO/2023/028077A1 |
The invention provides compounds of formulae I, II, Ila, and III, as described herein, and pharmaceutically acceptable salts thereof, as well as compositions containing such compounds and methods for using such compounds and compositions.
|
|
WO/2023/025776A1 |
The present invention relates to a process for preparing a fluorosulfonylimide salt. More specifically, the present invention relates to a process for preparing lithium bis(fluorosulfonyl)imide (LiFSI).
|
|
WO/2023/025854A1 |
The present invention relates to malonamide compounds of the formula (I) where the variables are as defined in the claims and the description, and to compositions comprising these compounds. The invention also relates to the use of said ...
|
|
WO/2023/020412A1 |
The present invention relates to a sulfonylurea compound represented by formula I, a preparation method therefore, and an application thereof. The compound of the present invention has soluble epoxide hydrolase (sEH) inhibitory activity ...
|
|
WO/2023/021895A1 |
Provided is an ionic liquid that can be used for semiconductor manufacturing and that has a low metal ion content. This ionic liquid comprises cations and anions and contains, each by not more than 100 ppb, metal ions of 16 elements in...
|
|
WO/2023/023310A1 |
The present invention provides compounds of Formula (I), pharmaceutical compositions comprising these compounds and methods of using these compounds to provides a method of modulating a HSD17B13 protein for treatment of metabolic disease...
|
|
WO/2023/019499A1 |
Disclosed in the present invention are an elastase inhibitor and the use thereof in disease treatment, which belongs to the field of medicines. Specifically, disclosed are a compound of formula (I), a pharmaceutical composition containin...
|
|
WO/2023/017474A1 |
This invention provides a flow synthesis process for producing sulfonylurea compounds of formula (1), including gliclazide, chlorpropamide and tolbutamide, and pharmaceutically acceptable salts thereof.
|
|
WO/2023/017475A1 |
This invention provides for a flow synthesis process for producing sulfonylurea compounds of formula (1), including glipizide and glibenclamide, and pharmaceutically acceptable salts thereof.
|
|
WO/2023/012610A1 |
The invention provides a pharmaceutical composition comprising compound of formula I alone or in combination along with other agents and pharmaceutical acceptable excipients for combinatorial therapy. The composition is a liquid formulat...
|
|
WO/2023/007188A1 |
The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof, Formula (I), wherein, the group X-Y is -NHSO2-; Z is a monocyclic or polycyclic cycloalkyl group or a monocyclic or pol...
|
|
WO/2023/008345A1 |
The present invention provides: an active light sensitive or radiation sensitive resin composition which contains a compound (I) that produces an acid when irradiated with active light or radiation, while having an ionic structure and a ...
|
|
WO/2023/001905A1 |
The present invention refers to a compound having the formula (I): R1–Z–C≡C–C≡C–R3 (I) and pharmaceutical compositions comprising the same that can be used in prevention, treatment and alleviation of a fungal infection. The i...
|
|
WO/2023/283743A1 |
The present invention provides compounds of formula (I): NR1R2SOOYR3 (I) or a pharmaceutically acceptable salt thereof. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), and use of the ...
|
|
WO/2023/281455A1 |
Present invention relates to development of compound of formula (I) for treatment of Cryopyrin Associated Periodic Syndromes (CAPS). Specifically, the present invention provides a NLRP3 inhibitors or its pharmaceutically acceptable salt ...
|
|
WO/2023/283586A2 |
Probenecid prodrug compounds, and formulations including one or more of probenecid, metabolites and analogs thereof, and prodrugs thereof, and pharmaceutically acceptable salt thereof are provided. Delivery vehicles and pharmaceutical co...
|
|
WO/2023/275607A1 |
Methods of producing N,N-dimethyl sulfamoyl fluoride and related derivatives of the formula F—S(O)2—NR2 (I) by contacting a sulfamoyl nonfluorohalide compound of the formula X—S(O)2—NR2 (II) with anhydrous hydrogen fluoride under...
|
|
WO/2022/270477A1 |
Provided are a compound represented by general formula (I), a polymerizable composition containing said compound, and a polymer and a polymer film having a structural component derived from said compound. In formula (I), R1 represents ...
|
|
WO/2022/270230A1 |
Provided is an active-light-sensitive or radiation-sensitive resin composition that yields a pattern having exceptional cross-sectional rectangularity. This active-light-sensitive or radiation-sensitive resin composition contains: a resi...
|
|
WO/2022/261992A1 |
Disclosed in the present invention is a method for preparing N-sulfimide, the method comprising: using ferric sulfate as a catalyst or using no catalyst and potassium hydrogen sulfate as an auxiliary agent to achieve a reaction of three ...
|
|
WO/2022/255770A1 |
The present invention relates to a novel squaramide derivative and a use thereof and provides a novel derivative through the strategy of replacing a compound having a urea core with the bioisolate squaramide, whereby the derivative exhib...
|
|
WO/2022/249994A1 |
This method for producing N-(hetero)aryl(meth)acrylamide compounds comprises obtaining a compound given by general formula (3) by carrying out an amidation reaction, at a temperature above 120°C, between a compound given by general form...
|
|
WO/2022/251567A1 |
Methods of making benzoxazepin oxazolidinone compounds as well as synthetic intermediates are described, including compound (10-2) and compound 18.
|
|
WO/2022/237780A1 |
An amide derivative and the pharmaceutical use thereof, in particular, the present invention relates to an amide derivative of formula (I) or a pharmaceutically acceptable salt thereof or all stereoisomers, tautomers and deuterated compo...
|
|
WO/2022/238696A1 |
The present disclosure describes a novel class of masking agents that can be activated under ionising radiation. The masking agents (which in some cases may be referred to as protecting groups) can be conjugated, linked or bonded to a pa...
|
|
WO/2022/235440A1 |
Method of treating a traumatic brain injury, a spinal cord injury, or stroke using small molecule CCR2 inhibitors. Also disclosed are kits and therapeutic uses of the small molecule CCR2 inhibitors.
|
|
WO/2022/220201A1 |
The present invention provides: an active light-sensitive or radiation-sensitive resin composition which contains a compound represented by general formula (S1) and an acid-decomposable resin; a resist film which is formed using this act...
|
|
WO/2022/211812A1 |
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present i...
|
